Navigation Links
Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
Date:11/20/2008

ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) announced today the global release of MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA are expected to allow researchers to successfully take the next step in their RNAi research with the highest purity and quality siRNA required for RNAi research in animal models. These siRNA are believed to be well suited to target validation and pre-clinical siRNA testing. Intermediate and large synthesis scales and a wide variety of modifications are also available.

"Increasingly, RNAi researchers are utilizing animal models to confirm findings from cell culture based assays or to explore the use of siRNA as a potential therapeutic agent," said Tim Fleming, Director of Global Commercial Marketing at Sigma-Aldrich. "Our goal is to provide an siRNA that is capable of facilitating in vivo siRNA research, with the purity levels required for direct delivery or to be used as an essential part of an overall in vivo formulation strategy."

MISSION(R) In VIVO QUALITY siRNA are processed specifically for in vivo usage. This purification process includes RP-HPLC to ensure a high percentage of full-length product (>94%), dialysis on the annealed product to remove excess salts, 22 micrometer sterile filtration, and finally testing to ensure no endotoxins are present.

In addition, iScale Oligos(TM) synthesis scales can give customers the large quantities of siRNA required for in vivo usage with amounts up to 100mg. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA are available with many of the common modifications used to for tracking or stability, such as FAM, Cy5(TM), and Cy3(TM).

"Sigma-Aldrich's MISSION(R) In VIVO QUALITY siRNAs are used exclusively at BIOO Scientific(TM) for all of our internal in vivo formulation development programs," said Lance Ford, Vice President of Research and Development at BIOO Scientific(TM) Corporation. "Most recently, we have used these siRNAs to with great success to demonstrate the utility of our new in vivo formulation, MaxSuppressor(TM) In Vivo RNA-LANCEr II (catalog #3410-01), in mouse models. BIOO Scientific(TM) Corporation recommends these siRNAs to our all of our customers as they are exceptional siRNAs, offered at a competitive price, with rapid turnaround times and supported by Sigma-Aldrich's professional service."

For more information on the MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, please visit sigma-aldrich.com/invivosirna .

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning website at http://www.sigma-aldrich.com.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research
3. Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
4. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
5. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
6. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
7. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
8. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
9. Sigma-Aldrich to Present at the UBS 2008 Global Life Sciences Conference on September 24, 2008
10. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
11. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... As part ... top industry experts, and expanding its LATAM network and logistics capabilities. Enhancements ... to manage their clinical trial projects. , The expansion will provide unmatched clinical ...
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the leading provider of ... that it has been named to The Silicon Review’s “20 Fastest Growing Big Data ... Cambridge Semantics serves the needs of end users facing some of the most complex ...
(Date:4/27/2016)... ... , ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” ... of Committee since 1987. Since then, he has served in a number of key ... for both the program and exposition committees. In his professional career, Dr. Gardner is ...
(Date:4/27/2016)... Columbia , April 27, 2016 ... "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... Anschluss an ihre Pressemitteilung vom 13. August 2015 ... hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten auf ... Kanadische Dollar zu bringen. Davon wurden 157.900.000 Einheiten ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):